Adagio Medical Q3 net loss $10.1M vs $4.6M; completes 209-patient VT trial, closes $50M placement

Adagio Medical Holdings, Inc.

2025-Q3 EPS reported -$1.42

Net loss of $10.1M in Q3 2025, vs $4.6M in Q3 2024; cash $4.7M as of Sep 30, 2025.
Completed enrollment of 209-patient FULCRUM-VT pivotal trial for vCLAS System VT ablation; demonstrated 97% acute effectiveness.
Closed private placement on Oct 20, 2025 with gross proceeds up to $50M; upfront ~$19M to fund PMA submission.
Appointed Deborah Kaster as Chief Financial Officer, adding to her role as Chief Business Officer.
R&D expenses $2.8M; SG&A expenses $2.9M, down from $7.8M in prior year quarter.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.